Ciputra Development Tbk vs Prodia Diagnostic Line Tbk — how do they compare? Ciputra Development Tbk trades at Rp595 (market cap 11.31T, 6.71M 24h volume), while Prodia Diagnostic Line Tbk trades at Rp270 (market cap 470.58B, 28.43M 24h volume). The key difference: Ciputra Development Tbk is far larger — about 24× Prodia Diagnostic Line Tbk's market cap, and Prodia Diagnostic Line Tbk is more actively traded (28.43M versus 6.71M). Which is the better fit depends on your goals.
| CTRA | PRDL | |
|---|---|---|
Market Cap | 11.31T | 470.58B |
Volume | 6.71M | 28.43M |
Lot | 67.06K | 284.34K |
Turnover | 4.02B | 7.8B |
Average Price | 598.92 | 274.19 |
Value | 4.02B | 7.8B |
Indicative Equilibrium Price | 595 | 270 |
Indicative Equilibrium Volume | 732 | 2.1K |
Trailing returns across standard periods
Latest headlines on both assets
PT Ciputra Development Tbk (the Company) was established in the Republic of Indonesia originally under the name PT Citra Habitat Indonesia based on notarial deed No. 22 dated October 22, 1981. Ciputra Developments main interest is in residential and township developments which account for approximately 90% of the companies total sales. The company has nine flagship development projects.
Read more on CTRA →PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →